Home » Stocks » TYME

Tyme Technologies, Inc. (TYME)

Stock Price: $1.01 USD -0.02 (-1.94%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 131.47M
Revenue (ttm) n/a
Net Income (ttm) -28.36M
Shares Out 130.17M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $1.01
Previous Close $1.03
Change ($) -0.02
Change (%) -1.94%
Day's Open 1.04
Day's Range 1.01 - 1.04
Day's Volume 180,800
52-Week Range 0.85 - 2.04

More Stats

Market Cap 131.47M
Enterprise Value 112.27M
Earnings Date (est) Feb 10, 2021
Ex-Dividend Date n/a
Shares Outstanding 130.17M
Float 60.72M
EPS (basic) -0.22
EPS (diluted) -0.23
FCF / Share -0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.42M
Short Ratio 13.46
Short % of Float 5.64%
Beta 0.77
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 9.25
Revenue n/a
Operating Income -28.43M
Net Income -28.36M
Free Cash Flow -22.76M
Net Cash 19.20M
Net Cash / Share 0.15
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -89.55%
ROE -260.08%
ROIC 1,061.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.75*
(766.34% upside)
Low
8.00
Current: $1.01
High
9.50
Target: 8.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue---------
Operating Income-25.76-31.78-19.36-15.21-8.60-2.58-0.06-0.03-
Net Income-22.00-32.98-18.97-15.21-11.73-2.65-0.06-0.03-
Shares Outstanding11510290.5784.4577.8568.0052.0047.6039.00
Earnings Per Share-0.19-0.32-0.21-0.18-0.15-0.04---
Operating Cash Flow-19.56-20.12-11.88-5.86-6.61-1.52-0.05-0.03-
Capital Expenditures--0.02-------
Free Cash Flow-19.56-20.13-11.88-5.86-6.61-1.52-0.05-0.03-
Cash & Equivalents26.7014.3028.9810.484.450.01-0.020.01
Total Debt0.570.600.48--1.35---
Net Cash / Debt26.1313.7028.5010.484.45-1.34-0.020.01
Assets29.5017.5231.0210.724.490.17-0.020.01
Liabilities10.487.854.553.331.472.640.04--
Book Value19.039.6726.477.393.02-2.47-0.040.010.01
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tyme Technologies, Inc.
Country United States
Employees 18
CEO Steve Hoffman

Stock Information

Ticker Symbol TYME
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TYME

Description

Tyme Technologies, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.